DNA vaccination in the skin using microneedles improves protection against influenza

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1472-1480

  Song, Jae Min ^a,b   Kim, Yeu Chun ^c,d   Eunju, O ^a   Compans, Richard W ^e   Prausnitz, Mark R ^c   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Sungshin Women's University   (South Korea)

^c Georgia Institute of Technology   (United States)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; DNA IMMUNIZATION; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; LOW DRUG DOSE; MICRONEEDLE PATCH; MOUSE; NEEDLE; NONHUMAN; SKIN CELL; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS TITRATION;

EID: 84863490212     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.69     Document Type: Conference Paper

References (49)

1. Jones, S, Evans, K, McElwaine-Johnn, H, Sharpe, M, Oxford, J, Lambkin-Williams, R et al. (2009). DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27: 2506-2512.
2. Wei, CJ, Boyington, JC, McTamney, PM, Kong, WP, Pearce, MB, Xu, L et al. (2010). Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
3. Ledgerwood, JE, Wei, CJ, Hu, Z, Gordon, IJ, Enama, ME, Hendel, CS et al. (2011). DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11: 916-924.
4. Wang, S, Parker, C, Taaffe, J, Solórzano, A, García-Sastre, A and Lu, S (2008). Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
5. Lu, S (2009). Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351.
6. Cattamanchi, A, Posavad, CM, Wald, A, Baine, Y, Moses, J, Higgins, TJ et al. (2008). Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 15: 1638-1643.
7. Kupper, TS and Fuhlbrigge, RC (2004). Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 4: 211-222. (Pubitemid 38339087)
8. Nagao, K, Ginhoux, F, Leitner, WW, Motegi, S, Bennett, CL, Clausen, BE et al. (2009). Murine epidermal Langerhans cells and langerin-expressing dermal dendritic cells are unrelated and exhibit distinct functions. Proc Natl Acad Sci USA 106: 3312-3317.
9. Howard, A, Mercer, P, Nataraj, HC and Kang, BC (1997). Bevel-down superior to bevel-up in intradermal skin testing. Ann Allergy Asthma Immunol 78: 594-596. (Pubitemid 27264195)
10. Bhowmik, T, D'Souza, B, Shashidharamurthy, R, Oettinger, C, Selvaraj, P and D'Souza, MJ (2011). A novel microparticulate vaccine for melanoma cancer using transdermal delivery. J Microencapsul 28: 294-300.
11. Glenn, GM, Kenney, RT, Ellingsworth, LR, Frech, SA, Hammond, SA and Zoeteweij, JP (2003). Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev Vaccines 2: 253-267. (Pubitemid 36559930)
12. Gill, HS, Andrews, SN, Sakthivel, SK, Fedanov, A, Williams, IR, Garber, DA et al. (2009). Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci 38: 95-103.
13. Feltquate, DM, Heaney, S, Webster, RG and Robinson, HL (1997). Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 158: 2278-2284. (Pubitemid 127470012)
14. Aihara, H and Miyazaki, J (1998). Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16: 867-870. (Pubitemid 28405859)
15. Prausnitz, MR, Mikszta, JA, Cormier, M and Andrianov, AK (2009). Microneedle-based vaccines. Curr Top Microbiol Immunol 333: 369-393.
16. Song, JM, Kim, YC, Barlow, PG, Hossain, MJ, Park, KM, Donis, RO et al. (2010). Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 88: 244-247.
17. Sullivan, SP, Koutsonanos, DG, Del Pilar Martin, M, Lee, JW, Zarnitsyn, V, Choi, SO et al. (2010). Dissolving polymer microneedle patches for influenza vaccination. Nat Med 16: 915-920.
18. Zhu, Q, Zarnitsyn, VG, Ye, L, Wen, Z, Gao, Y, Pan, L et al. (2009). Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc Natl Acad Sci USA 106: 7968-7973.
19. Gill, HS, Söderholm, J, Prausnitz, MR and Sällberg, M (2010). Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther 17: 811-814.
20. Garg, S, Oran, AE, Hon, H and Jacob, J (2004). The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173: 550-558. (Pubitemid 38797383)
21. Bosio, CM and Dow, SW (2005). Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol 175: 6792-6801. (Pubitemid 41598924)
22. McGill, J, Van Rooijen, N and Legge, KL (2008). Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J Exp Med 205: 1635-1646.
23. Song, JM, Wang, BZ, Park, KM, Van Rooijen, N, Quan, FS, Kim, MC et al. (2011). Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 6: e14538.
24. Song, JM, Van Rooijen, N, Bozja, J, Compans, RW and Kang, SM (2011). Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci USA 108: 757-761.
25. Akbari, O, Panjwani, N, Garcia, S, Tascon, R, Lowrie, D and Stockinger, B (1999). DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 189: 169-178.
26. Kenney, RT, Frech, SA, Muenz, LR, Villar, CP and Glenn, GM (2004). Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351: 2295-2301. (Pubitemid 39552745)
27. Van Damme, P, Oosterhuis-Kafeja, F, Van der Wielen, M, Almagor, Y, Sharon, O and Levin, Y (2009). Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27: 454-459.
28. Alarcon, JB, Hartley, AW, Harvey, NG and Mikszta, JA (2007). Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin Vaccine Immunol 14: 375-381. (Pubitemid 46732547)
29. Patel, A, Tran, K, Gray, M, Li, Y, Ao, Z, Yao, X et al. (2009). Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 27: 3083-3089.
30. Johnson, PA, Conway, MA, Daly, J, Nicolson, C, Robertson, J and Mills, KH (2000). Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol 81(Pt 7): 1737-1745. (Pubitemid 30427079)
31. Pertmer, TM, Roberts, TR and Haynes, JR (1996). Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 70: 6119-6125. (Pubitemid 26266828)
32. Hinton, HJ, Jegerlehner, A and Bachmann, MF (2008). Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr Top Microbiol Immunol 319: 1-15.
33. Mozdzanowska, K, Feng, J, Eid, M, Kragol, G, Cudic, M, Otvos, L Jr et al. (2003). Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626. (Pubitemid 36561354)
34. Huber, VC, McKeon, RM, Brackin, MN, Miller, LA, Keating, R, Brown, SA et al. (2006). Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13: 981-990. (Pubitemid 44518965)
35. Huber, VC, Lynch, JM, Bucher, DJ, Le, J and Metzger, DW (2001). Fc receptormediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166: 7381-7388. (Pubitemid 32525614)
36. Klaus, GG, Pepys, MB, Kitajima, K and Askonas, BA (1979). Activation of mouse complement by different classes of mouse antibody. Immunology 38: 687-695. (Pubitemid 10145294)
37. Nimmerjahn, F and Ravetch, JV (2005). Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512. (Pubitemid 41746349)
38. Prow, TW, Chen, X, Prow, NA, Fernando, GJ, Tan, CS, Raphael, AP et al. (2010). Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6: 1776-1784.
39. Quan, FS, Huang, C, Compans, RW and Kang, SM (2007). Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81: 3514-3524. (Pubitemid 46456660)
40. González-González, E, Ra, H, Spitler, R, Hickerson, RP, Contag, CH and Kaspar, RL (2010). Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters. Gene Ther 17: 1270-1278.
41. Kim, YC, Quan, FS, Compans, RW, Kang, SM and Prausnitz, MR (2010). Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J Control Release 142: 187-195.
42. Contag, CH and Bachmann, MH (2002). Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4: 235-260. (Pubitemid 35217421)
43. Song, JM, Kim, YC, Lipatov, AS, Pearton, M, Davis, CT, Yoo, DG et al. (2010). Microneedle delivery of H5N1 influenza virus-like particles to the skin induces longlasting B-and T-cell responses in mice. Clin Vaccine Immunol 17: 1381-1389.
44. Kim, YC, Quan, FS, Yoo, DG, Compans, RW, Kang, SM and Prausnitz, MR (2009). Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 27: 6932-6938.
45. Song, JM, Hossain, J, Yoo, DG, Lipatov, AS, Davis, CT, Quan, FS et al. (2010). Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405: 165-175.
46. Deng, Y, Yewdell, JW, Eisenlohr, LC and Bennink, JR (1997). MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 158: 1507-1515. (Pubitemid 127469502)
47. Oran, AE and Robinson, HL (2003). DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4+ and CD8+ T cells. J Immunol 171: 1999-2005. (Pubitemid 36974544)
48. Van Rooijen, N and Sanders, A (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
49. Thepen, T, McMenamin, C, Oliver, J, Kraal, G and Holt, PG (1991). Regulation of immune response to inhaled antigen by alveolar macrophages: differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity. Eur J Immunol 21: 2845-2850.